Niraparib treatment for recurrent IDH1/2 gliomas

A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas

This study is testing if the drug niraparib can help people with recurrent gliomas that have IDH1 or IDH2 mutations by giving it to them before or after surgery.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Massachusetts General Hospital (Academic / other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (Boston, Massachusetts)
• Trial ID: NCT05406700 on ClinicalTrials.gov

What this trial studies

This pilot study investigates the effects of niraparib, an experimental treatment, on patients with recurrent gliomas that have IDH1 or IDH2 mutations. Participants will be randomized into two groups: one receiving niraparib before surgery and the other receiving it after surgery. The study aims to assess the drug's pharmacokinetics and pharmacodynamics within tumor tissue. Participants will be monitored for up to five years following treatment, with a total of 16 individuals expected to enroll.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with confirmed IDH1 or IDH2 mutant gliomas that have shown progression or recurrence.

Not a fit: Patients with gliomas that do not have IDH1 or IDH2 mutations or those who are not surgical candidates may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with recurrent IDH1/2 mutant gliomas.

How similar studies have performed: While niraparib has been approved for other uses, this specific application in IDH1/2 mutant gliomas is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

* Participants must be ≥18 years of age.
* Participants must have histologically or cytologically confirmed glioma, with documented IDH1 and/or IDH2 gene-mutation at time of initial diagnosis
* Participants must have radiographic evidence of progression/recurrence per RANO criteria for low grade gliomas (LGG) on MRI scan
* Participants must be willing and able to get serial MRI scans
* Participants must have surgically accessible tumors and be surgical candidates.
* Participants must be ≥12 weeks from completion of radiation to the CNS.
* Participants must have a baseline brain MRI scan within 21 days prior to Day 1 of treatment.
* Participants must be on a stable or decreasing dose of glucocorticoids for 7 days prior to registration.
* Patient must have Karnofsky Performance Score (KPS) ≥ 70
* Patient must have expected survival of ≥ 6 months.
* Participant must have adequate organ function, defined as follows:

  * Absolute neutrophil count ≥ 1,500/μL
  * Platelets ≥ 100,000/μL
  * Hemoglobin ≥ 9 g/dL
  * Calculated creatinine clearance ≥ 30 mL/min/1.73 m2 using the Cockcroft- Gault equation
  * Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN
  * Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
* Patient must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (Patients with residual Grade 1 toxicity due to prior chemotherapy or alopecia of any grade are allowed).
* Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
* Female participant has a negative urine or serum pregnancy test within 3 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of non-childbearing potential. Non-childbearing potential is defined as follows (by other than medical reasons):

  * ≥45 years of age and has not had menses for \>1 year
  * Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
  * Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.
* Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent

Exclusion Criteria:

* Participants must have radiographic evidence of primarily disease progression/recurrence per RANO criteria for low grade gliomas (LGG).
* Participant must not be simultaneously enrolled in any interventional clinical trial
* Participant must not have had major surgery ≤ 4 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
* Patients may not have received systemic anticancer therapy \<28 days prior to their first day of study drug administration. Participants may not have received lomustine \< 6 weeks prior to the first day of study drug.
* Patients who received an investigational agent \<28 days prior to their first day of study drug administration.
* Participant must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy. Participant must not have received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
* Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted \> 4 weeks and was related to the most recent treatment.
* Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
* Participant must not have had diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated).
* Participants who are pregnant or breast-feeding.
* Participants with known hypersensitivity to any of the components of niraparib.
* Participants with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
* Participants with any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate, or participate in the study.
* Participants with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
* Participants that have had radiation therapy encompassing \>20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.
* Participant must not have known or symptomatic leptomeningeal metastases.

Where this trial is running

Boston, Massachusetts

• Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)

Study contacts

• Principal investigator: Isabel Arrillaga-Romany, MD, Phd — Massachusetts General Hospital
• Study coordinator: Isabel Arrillaga-Romany, MD, PhD

Conditions Low-grade Glioma; IDH2 Gene Mutation; Recurrent Glioma; IDH1 Mutation; Glioma, Malignant